The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications

Diabetic Medicine

Volumn 15, Issue 3, 1998, Pages 188-193

  Ceriello, Antonio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Diabetic complications; Labile glycation; Oxidative stress; Post prandial hyperglycaemia

Indexed keywords

AUTOOXIDATION; BLOOD CLOTTING; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; REVIEW; VASOCONSTRICTION;

DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; FOOD; GASTROINTESTINAL DISEASES; HUMANS; HYPERGLYCEMIA;

EID: 0031929810     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199803)15:3<188::AID-DIA545>3.0.CO;2-V     Document Type: Review

References (82)

1. The Diabetes Control and Complications Trials (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Santiago JV. Lessons from the diabetes control and complications trial. Diabetes 1993; 42: 1549-1554.
3. American Diabetes Association. Position statement: implications of the diabetes control and complications trial. Diabetes 1993; 42: 1555-1558.
4. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-983.
5. Skott P, Vaag A, Hother-Nielsen O, Andersen P, Brunne NE, Giese J, et al. Effects of hyperglycemia on kidney function, atrial natriuretic factor and plasma renin in patients with insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 1991; 51: 715-727.
6. Wiseman MJ, Saunders AJ, Keen H, Viberti GC. Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N Engl J Med 1985; 312: 617-621.
7. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, De Fronzo RA. Effect of strict glycemic control on renal haemodynamic response to aminoacids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991; 324: 1626-1632.
8. Remuzzi A, Viberti GC, Ruggenenti P, Battaglia C, Pagni R, Remuzzi G. Glomerular response to hyperglycemia in human diabetic nephropathy. Am J Phsyiol 1990; 259: F545-F552.
9. De Cosmo S, Earle K, Morocutti A, Walker J, Ruggenenti P, Remuzzi G, Viberti GC. Glucose-induced changes in renal haemodynamics in proteinuric type I (insulin-dependent) diabetic patients: inhibition by acetylsalicylic acid infusion. Diabetologia 1993; 36: 622-627.
10. Takeuchi A, Throckmorton DC, Brogden AP, Yoshizawa N, Rasmussen H, Kashgarian M. Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 1995; 268: F13-F19.
11. Steffes MW, Bilous RW, Sutherland DER, Mauer SM. Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes 1992; 41: 679-684.
12. Hasslacher C, Ritz E. Effect of control of diabetes mellitus on progression of renal failure. Kidney Internat 1987; 32 (suppl 22): 53-56.
13. Kohner EM, Patel V, Rassam SMB. Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. Diabetes 1995; 44: 603-607.
14. Grunwald JE, Bruckner AJ, Schwartz SS, Braunstein SN, Baker L, Petrig BL, Riva CE. Diabetic glycemic control and retinal blood flow. Diabetes 1990; 39: 602-607.
15. Patel V, Rassam SMB, Chen HC, Kohner EM. Oxygen reactivity in diabetes mellitus: effect of hypertension and hyperglycemia. Clin Sci 1994; 86: 689-695.
16. Rassam SMB, Patel V, Kohner EM. The effect of experimental hypertension on retinal autoregulation in humans: a mechanism for the progression of diabetic retinopathy. Exp Phsyiol 1995; 80: 53-68.
17. Atherton A, Hill DW, Keen H, Young S, Edwards EJ. The effect of acute hyperglycemia on the retinal circulation of the normal cat. Diabetologia 1980; 18: 233-237.
18. Sullivan PM, Davies EG, Caldwell G, Morris AH, Kohner EM. Retinal blood flow during hyperglycemia. Invest Ophthalmol Visual Sci 1990; 31: 2041-2045.
19. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978; 1: 139-140.
20. Young RJ, Macintyre CA, Martin CN, Prescott RJ, Ewing DJ, Smith AF, et al. Progression of subclinical neuropathy in young patients with type I (insulin-dependent) diabetes: associated with glycemic control and microangiopathy (microvascular complications). Diabetologia 1986; 29: 156-161.
21. Masaoka S, Lev-Ran A, Hill LR, Vakil G, Hon EHG. Heart rate variability in diabetes: relationship to age and duration of the disease. Diabetes Care 1985; 8: 64-68.
22. Ward JD, Fisher DJ, Barnes CG, Jesop JD. Improvement in nerve conduction following treatment in newly diagnosed diabetics. Lancet 1971; 1: 428-430.
23. Gregersen G. Variations in motor conduction velocity produced by acute changes of the metabolic state in diabetic patients. Diabetologia 1968; 4: 273-277.
24. Yeap BB, Russo A, Fraser RJ, Wittert GA, Horowitz M. Hyperglycemia affects cardiovascular autonomic nerve function in normal subjects. Diabetes Care 1996; 19: 880-882.
25. Marfella R, Verrazzo G, Acampora R, La Marca C, Giunta R, Lucarelli C, et al. Glutathione reverses systemic hemodynamic changes by acute hyperglycemia in healthy subjects. Am J Physiol 1995; 268: E1167-E1173.
26. Lee JH, McCarty R. Glycemic control of pain threshold in diabetic and control rats. Physiol Behav 1990; 47: 225-230.
27. Thye-Ronn P, Sindrup SH, Arendt-Nielsen L, Brennum J, Hother-Nielsen O, Beck-Hielsen H. Effect of short-term hyperglycemia per se on nociceptive and non-nociceptive thresholds. Pain 1994; 56: 43-49.
28. Gonder-Frederick LA, Cox DJ, Bobbitt SA, Pennebaker JW. Mood changes associated with blood glucose fluctuations in insulin-dependent diabetes mellitus. Health Psychol 1989; 8: 45-59.
29. Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 1994; 37: 543-551.
30. Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BE, Shearman DJC. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991; 18: 229-234.
31. Fraser R, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 30: 675-680.
32. Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 1988; 94: 739-744.
33. Fraser R, Horowitz M, Dent J. Hyperglycemia stimulates pyloric motility in normal subjects. Gut 1991; 32: 475-478.
34. Oster-Jorgensen E, Pedersen SA, Larsen ML. The influence of induced hyperglycemia on gastric emptying in healthy humans. Scand J Clin Lab Invest 1990; 50: 831-836.
35. Groop LC, De Fronzo RA, Luizi L, Melander A. Hyperglycemia and absorption of sulphonylurea drugs. Lancet 1989; 2: 129-130.
36. Hoffman A, Fisher Y, Gilhar D, Raz I. The effect of hyperglycemia on the absorption of glibenclamide in patients with non-insulin dependent diabetes mellitus. Eur J Clin Pharmacol 1994; 47: 53-55.
37. de Boer SY, Masclee AAM, Lam WF, Lamers CBHW. Effect of acute hyperglycemia on esophageal motility and lower esophageal sphincter pressure in humans. Gastroenterology 1992; 103: 775-780.
38. de Boer SY, Masclee AA, Lam WF, Schipper J, Jansen JB, Lamers CB. Hyperglycemia modulates gallbladder motility and small intestinal transit time in man. Dig Dis Sci 1993; 38: 228-2235.
39. de Boer SY, Masclee AAM, Lam WF, Lemkes HHPJ, Schipper J, Fröhlich M, et al. Effect of hyperglycemia on gallbladder motility in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1994; 37: 75-81.
40. Lieber M. The incidence of gallstones and their correlation with other diseases. Ann Surg 1952; 135: 394-404.
41. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-267.
42. Drury PL. Diabetes and arterial hypertension. Diabetologia 1983; 24: 1-9.
43. Ceriello A, Quatraro A, Giugliano D. Diabetes mellitus and hypertension. The possible role of hyperglycaemia through oxidative stress. Diabetologia 1993; 36: 265-266.
44. Haffner S, Valdez R, Morales PA, Mitchell BD, Hazuda HP, Stern MP. Greater effect of glycemia on incidence of hypertension in women than in man. Diabetes Care 1992; 15: 1277-1284.
45. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 1991; 87: 1643-1648.
46. Bohlen HG, Lash JM. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol 1993; 265: H219-H225.
47. Ceriello A, Motz E, Cavarape A, Lizzio S, Russo A, Quatraro A, Giugliano D. Hyperglycemia counterbalances the anti-hypertensive effect of glutathione in diabetic patients. Evidence linking hypertension and glycemia through the oxidative stress in diabetes mellitus. J Diab Compl 1997; 11: 250-255.
48. Bellodi G, Manicardi V, Malavasi V, Veneri L, Bernini G, Bossini P, et al. Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol 1989; 64: 885-888.
49. O'Sullivan JJ, Conroy RM, Robinson K, Hickey N, Mulcahy R. In hospital prognosis of patients with fasting hyperglycemia after first myocardial infarction. Diabetes Care 1991; 14: 758-760.
50. Gray CS, Taylor R, French JM, Alberti KG, Venables GS, James OF, et al. The prognostic value of stress hyperglycemia and previously unrecognized diabetes in acute stroke. Diabetic Med 1987; 4: 237-240.
51. Gray CS, French JM, Bates D, Cartlidge NE, Venables GS, James OF. Increasing age, diabetes mellitus and recovery from stroke. Postgrad Med J 1989; 65: 720-742.
52. Duchrow RB, Beard DC, Brennan RW. Regional cerebral blood flow decrease during chronic and acute hyperglycemia. Stroke 1987; 18: 52-58.
53. de Falco FA, Sepe-Visconti O, Fucci G, Caruso G. Correlation beween hyperglycemia and cerebral infarct size in patients with stroke. A clinical and X-ray computed tomography study in 104 patients. Schweiz Arch Neurol Psychiatr 1993; 144: 233-239.
54. Malberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
55. Jones RL, Peterson CM. Reduced fibrinogen survival in diabetes mellitus: a reversible phenomenon. J Clin Invest 1979; 63: 485-493.
56. Jones RL. Fibrinopeptide A in diabetes mellitus: relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes. Diabetes 1985; 34: 836-841.
57. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Marchi E, Torella R. Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism 1989; 38: 1162-1163.
58. Ceriello A, Giacomello R, Stel G, Motz E, Toboga C, Tonutti L, et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995; 44: 924-928.
59. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 1988; 31: 889-891.
60. Ceriello A, Toboga C, Tonutti L, Giacomello R, Stel G, Motz E, Pirisi M. Post-meal coagulation activation in diabetes mellitus: the effect of Acarbose. Diabetologia 1996; 39: 469-473.
61. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1119-1125.
62. Ruosladti E. Integrins. J Clin Invest 1991; 187: 1-5.
63. Lopes-Virella MF, Virella G. Immune mechanism of atherosclerosis in diabetes mellitus. Diabetes 1992: 41 (suppl 2): 86-91.
64. Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemostas 1994; 72: 151-154.
65. Ceriello A, Falleti E, Giacomello R, Stel G, Motz E, Taboga C, et al. Evidence for a correlationship between coagulation activation and adhesion molecule ICAM-1 increase in diabetes (Abstract). Diabetes 1995; 44 (suppl 1): 636.
66. Ceriello A, Falleti E, Bortolotti N, Metz E, Cavarape A, Russo A, Gonano F, Bartoli E. Increased circulating ICAM-1 levels in Type-2 diabetic patients: the possible role of metabolic control and oxidative stress. Metabolism 1996; 45: 498-501.
67. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-512.
68. Ceriello A, Falleti E, Bortolotti N, Motz E, Cavarape A, Russo A, Gonano F, Bartoli E. Increased circulating ICAM-1 levels in Type-2 diabetic patients: the possible role of the oxidative stress and metabolic control (Abstract). Diabetologia 1995; 38 (suppl 1): 154.
69. Reynolds TM. Chemistry of nonenzymatic browning. I. Adv Food Res 1963; 12: 1-52.
70. Reynolds TM. Chemistry of nonenzymatic browning. II. Adv Food Res 1965; 14: 167-283.
71. Ceriello A, Quatraro A, Giugliano D. New insights on non-enzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. Diabetic Med 1992; 9: 297-299.
72. Ceriello A, Giugliano D. Oxidative stress and diabetic complications. In: Alberti KGMM, Zimmet P, De Fronzo RA, eds. International Textbook of Dibetes Mellitus, 2nd edn. Chichester: Wiley, 1997: 1453-1461.
73. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990; 173: 932-939.
74. Wolff SP, Dean RT. Glucose auto-oxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J 1987; 245: 243-250.
75. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Lower plasma peroxyl radical trapping capacity and higher susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994; 43: 1010-1014.
76. Ceriello A, Bortolotti N, Falleti E, Taboga C, Tonutti L, Crescentini A, et al. Total radical-trapping antioxidant parameter in non-insulin dependent diabetic patients. Diabetes Care 1997; 20: 194-197.
77. Ceriello A, Bortolotti N, Crescentini A, Motz E, Lizzio S, Russo A, et al. Antioxidant defenses are reduced during meal in normal and NIDDM subjects (Abstract). Diabetes 1997; 46 (suppl 1): 1402.
78. Holleman F, Hoekstra JBL. Drug therapy: insulin Lispro. N Engl J Med 1997; 337: 176-183.
79. Chiasson JL, Josse RG, Hung JA, Palmason C, Rodger NW, Ross SA, et al. The efficacy of Acarbose in the treatment of patients with non insulin dependent diabetes mellitus. Ann Int Med 1994; 121: 928-935.
80. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, Kamada T. 1,5-anhydro-d-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 1995; 18: 1156-1159.
81. Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycemic control. Lancet 1996; 347: 1514-1518.
82. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. Diabetes 1996; 45: 1289-1298.